tiprankstipranks
Vaccinex Inc (VCNX)
NASDAQ:VCNX
US Market

Vaccinex (VCNX) Income Statement

278 Followers

Vaccinex Income Statement

Last quarter (Q4 2023), Vaccinex's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Vaccinex's net income was $-3.32M. See Vaccinex’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 775.00K$ 570.00K$ 275.00K$ 900.00K$ 50.00K$ 523.00K
Cost of Revenue
----$ 2.00K$ 199.00K
Gross Profit
$ 775.00K$ 570.00K$ 275.00K$ 900.00K$ 48.00K$ 324.00K
Operating Expense
$ 22.95M$ 23.45M$ 20.18M$ 23.39M$ 28.38M$ 32.34M
Operating Income
$ -22.17M$ -22.89M$ -19.91M$ -22.49M$ -28.33M$ -32.02M
Net Non Operating Interest Income Expense
-$ -1.00K$ -2.00K$ -809.00K$ -489.00K$ 0.00
Other Income Expense
$ 2.08M$ 1.19M$ -93.00K$ -919.00K$ -31.00K$ 152.00K
Pretax Income
$ -20.45M$ -20.30M$ -19.80M$ -22.38M$ -28.85M$ -31.86M
Tax Provision
---$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -20.42M$ -20.25M$ -19.82M$ -22.38M$ -28.85M$ -31.86M
Basic EPS
$ 17.33$ -43.68$ -0.47$ -0.78$ -1.54$ -2.47
Diluted EPS
$ 17.45$ -43.68$ -0.47$ -0.78$ -1.54$ -2.47
Basic Average Shares
$ 153.75M$ 463.65K$ 42.44M$ 28.85M$ 18.79M$ 12.88M
Diluted Average Shares
$ 153.75M$ 463.65K$ 42.44M$ 28.85M$ 18.79M$ 12.88M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 22.95M$ 23.45M$ 20.18M$ 23.39M$ 28.38M$ 32.54M
Net Income From Continuing And Discontinued Operation
$ -20.42M$ -20.25M$ -19.82M$ -22.38M$ -28.85M$ -31.86M
Normalized Income
$ -8.24M$ -16.04M$ -15.64M-$ -28.85M$ -31.86M
Interest Expense
----$ 489.00K$ 0.00
EBIT
$ -20.45M$ -20.30M$ -19.80M$ -21.57M$ -28.36M$ -31.86M
EBITDA
$ -13.29M$ -20.18M$ -19.59M$ -21.40M$ -28.05M$ -31.61M
Currency in USD

Vaccinex Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis